The ROE as of September 2024 (TTM) for Tarsus Pharmaceuticals, Inc. (TARS) is -63.99%

According to Tarsus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -63.99%. This represents a change of 289.14% compared to the average of -16.44% of the last 4 quarters.

Tarsus Pharmaceuticals, Inc. (TARS) Historical ROE (quarterly & annually)

How has TARS ROE performed in the past?

The mean historical ROE of Tarsus Pharmaceuticals, Inc. over the last ten years is 8.26%. The current -63.99% ROE has changed -874.62% with respect to the historical average. Over the past ten years (40 quarters), TARS's ROE was at its highest in in the September 2020 quarter at 56.86%. The ROE was at its lowest in in the June 2023 quarter at -21.27%.

Tarsus Pharmaceuticals, Inc. (TARS) ROE by Quarter and Year

Discovering the peaks and valleys of Tarsus Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Tarsus Pharmaceuticals, Inc. (TARS) Average ROE

How has TARS ROE performed in the past?

The current ROE of Tarsus Pharmaceuticals, Inc. (TARS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Tarsus Pharmaceuticals, Inc. (TARS) ROE vs. Peers

How is TARS’s ROE compared to its peers?

Tarsus Pharmaceuticals, Inc.’s ROE is greater than LianBio (-38.06%), greater than Aldeyra Therapeutics, Inc. (-33.33%), greater than Travere Therapeutics, Inc. (-102.43%), greater than Eton Pharmaceuticals, Inc. (-43.62%), greater than Connect Biopharma Holdings Limited (-3.40%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Nuvation Bio Inc. (-98.79%), greater than Eledon Pharmaceuticals, Inc. (-124.74%), less than Opthea Limited (360.05%), greater than Centessa Pharmaceuticals plc (-63.22%), greater than Nuvalent, Inc. (-28.83%), greater than Genfit S.A. (-60.96%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Ikena Oncology, Inc. (-42.81%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than PepGen Inc. (-62.74%), greater than Tyra Biosciences, Inc. (-27.13%), less than Entrada Therapeutics, Inc. (35.16%), greater than Pharvaris N.V. (-36.89%), greater than Rallybio Corporation (-74.08%),

Build a custom stock screener for Tarsus Pharmaceuticals, Inc. (TARS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tarsus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Tarsus Pharmaceuticals, Inc. (TARS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Tarsus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.